A Study of IMR-687 in Healthy Adult Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 6/3/2018 |
| Start Date: | October 18, 2016 |
| End Date: | July 8, 2017 |
A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled
study is to evaluate the safety, tolerability, PK and PD profile of the orally administered
IMR-687 in healthy adult subjects.
study is to evaluate the safety, tolerability, PK and PD profile of the orally administered
IMR-687 in healthy adult subjects.
Inclusion Criteria:
- Be healthy as judged by the Investigator on the basis of pre-study tests performed at
Screening, with healthy body mass index (BMI), healthy body weight, and laboratory
results within normal laboratory reference range or determined not to be clinically
significant by the Investigator; and be free from drugs of abuse.
Exclusion Criteria:
- Females who are pregnant, trying to become pregnant, or breastfeeding; and males with
female partners who are trying to conceive.
- Asthmatics or other individuals who use or may use albuterol rescue inhalers or
nebulizers.
- A significant history of cardiovascular disease.
- On ECG, a QTcF >450 ms or the presence of clinically significant abnormalities as
determined by the Investigator.
- Elevated blood pressure.
- Use within 30 days prior to Day 1 of any inhibitors or substrates of targets of
IMR-687.
We found this trial at
1
site
Click here to add this to my saved trials
